Kornimate/medical-research-clean huggingface dataset:
diet in twin pregnancy: the wellness of mother and babies.

Conditions: Twin Pregnancy, Antepartum Condition or Complication; Gestational Diabetes; Gestational Hypertension; Intrahepatic Cholestasis of Pregnancy; Food Habits; Diet, Healthy

Summary: the aim of this study is to evaluate how variations in maternal nutrition may affect twin pregnancy and in particular: * incidence of maternal obstetric complications: * gestational diabetes * gestational hypertension or preeclampsia * intrahepatic cholestasis (icp) * fetal growth, development and birth weight of the babies

study design at the time of recruitment, each patient will perform an initial clinical nutrition examination, during which will be evaluated, on the basis of bmi and specific anthropometric parameters, the necessary nutritional intake. patients included in the study will then be classified, on the basis of pre-pregnancy bmi, into 2 classes: * normal weight (bmi 18-25) * overweight (bmi 25-30) a specific diet will be developed for each patient, which will also take into account any food allergies or intolerances. each diet will be then eventually modified and revised throughout the pregnancy, according to the evolution of the same. patients will then continue their regular obstetrical examinations at the obstetrical day hospital, every 4 weeks in case of uncomplicated dichorionic twin pregnancy and every 2 weeks in case of uncomplicated monochorionic twin pregnancy. once a month, in coincidence with the appointment at the obstetric day hospital, the enrolled patients will be evaluated by the dedicated team of nutritionists.

Eligibility criteria:
inclusion criteria: * dichorionic-diamniotic twin pregnancies * monochorionic-diamniotic twin pregrancies * monochorionic- monoamniotic twin pregnancies * spontaneous onset or by homologous pma techniques * age between 18 and 40 years * gestational age between 8 weeks+0 days and 25 weeks+6 days exclusion criteria: * pregestational diabetes mellitus (type i and ii) * chronic hypertension * previous bariatric surgery * chronic gastrointestinal disease (celiac disease, crohn's disease, ulcerative rectocolitis) * age less than 18 years or more than 40 years * gestational age less than 8 weeks or more than 26 weeks * fetal structural and/or genetic abnormalities * heterologous pma * maternal eating disorders * drug and/or alcohol use * multiple pregnancies with more than two babies
aspects associated with sleep quality

Conditions: Sleep Bruxism

Summary: evaluate the correlation among the diagnostics of sleep bruxism and sleep quality obtained from the use of smartphone application (app-sleep cycle®), psg and questionnaires (pittsburgh sleep quality index-iqsp and johansson).

this study will evaluate the correlation between sleep bruxism and sleep quality diagnoses obtained using the application of the smartphone (app-sleep cycle®), polysomnography and questionnaires (pittsburgh sleep quality index-iqsp and johansson). subjects (n = 40) between 19 and 60 years old will be submitted to polysomnography from january to december 2019. the questionnaires will be applied before the polysomnography, and the app will be used together with the polysomnography. the data will be tabulated and a descriptive statistical analysis performed. specific statistical tests will be determined after preliminary analysis of the data (α = 0.05).

Eligibility criteria:
inclusion criteria: * adults (aged 20 to 60 years) and elderly (aged \> 60 years) (who-world health organization, 2015) who will be undergone psg at the pelotas sleep institute (isp); * adequate cognitive capacity to understand and answer the questionnaire. exclusion criteria: • those which the participants were unable to answer the questionnaires and who presented a history of epilepsy that could interfere in the results of psg.

Keywords: sleep bruxism sleep sleep hygiene
study to evaluate the sensitivity of the linda thermal device

Conditions: Device; Thermography; Mammography

Summary: the linda thermal device consists of a thermal camera attachable to a cell phone and an application for connection with an artificial intelligence program based on a convolutional neural network for classification of thermographic breast images. the system is previously fed with thermographic images of the breast and their respective results/diagnostics. the images are processed in an automated way and return a percentage of chance of having a pathological pattern.

the linda thermal device consists of a thermal camera attachable to a cell phone and an application for connection with an artificial intelligence program based on a convolutional neural network for classification of thermographic breast images. the system is previously fed with thermographic images of the breast and their respective results/diagnostics. the images are processed in an automated way and return a percentage of chance of having a pathological pattern. nfrared imaging (thermography) was approved as an auxiliary imaging modality for mammography by the food and drug administration (fda) in 1982. thermography is a non-invasive, non-contact method without ionizing radiation, which is why its use can be prolonged and repeated. this technique allows for an evaluation of the functionality of the structures, which is why it is considered a physiological test and records the variation in the surface temperature of the human body based on the infrared radiation emitted by the surface of that body. it is capable of detecting tumor lesions since cancer cells generate heat due to the release of nitric oxide in the blood, causing changes in microcirculation, vasodilation, neo-angiogenesis and increased metabolic activity of cancer cells. thus, in the initial stage of breast cancer, when it has not yet caused anatomical changes, there will be physiological changes that will lead to an increase in blood flow and metabolic activity. this increase induces a temperature rise in the area which will then be detected by thermography.

Eligibility criteria:
inclusion criteria: 1. provide your signed and dated consent in duplicate; 2. female, aged between 40 and 69 years; 3. have had a mammography no more than 6 months before v1 and with results available in v1. exclusion criteria: 1. fever (temperature above 37.8°c at rest) in the last 48 hours before image capture by thermography; 2. exposure to natural or artificial light for chest tanning for less than three (3) days before performing the thermography; 3. pregnant or breastfeeding women in the last 6 months; 4. physical exercise 3 h before performing the thermography; 5. to have performed a breast biopsy less than 6 months after the thermography; 6. other conditions that, at the investigator's discretion, increase the risk to the patient or make her unsuitable for the study.
outcomes of thyroid auto transplantation following total thyroidectomy in benign thyroid disorders protocol

Conditions: Thyroid Diseases

Summary: the study aimed at evaluating efficacy of auto-transplantation of thyroid tissue after total thyroidectomy in benign thyroid disorders to keep the patient euthyroid with no need for life long hormone replacement therapy.

this study will be a prospective study which will be conducted at sohag university hospital after approval of the protocol the study population include . adult patients with goiters are seen in the general surgery outpatient clinic the study included thirty studied cases presented in the outpatient clinic with benign thyroid disorders for whom total thyroidectomy was performed

Eligibility criteria:
inclusion criteria: * patients proved to have benign thyroid disorders operable and candidate for total thyroidectomy adult patients who agreed and consented to do the procedure. exclusion criteria: * patients with high suspicion of malignancy , unfit and refused the procedure
gm-csf inhalation to prevent ards in covid-19 pneumonia

Conditions: Severe Acute Respiratory Syndrome (SARS) Pneumonia; COVID-19 Pneumonia

Summary: to assess the safety and tolerability of inhaled molgramostim nebuliser solution in patients with covid-19 pneumonia.

covid-19 pneumonia is induced by the newly emerging pandemic severe acute respiratory syndrome (sars) coronavirus 2 and results in progression to the acute respiratory distress syndrome (ards). apart from protective ventilation, fluid restriction, prone positioning and extracorporeal membrane oxygenation (ecmo), no specific therapeutic options exist to treat this devastating disease with a mortality rate of up to 50%. the growth factor granulocyte-macrophage colony-stimulating factor (gm-csf) is widely recognized to promote differentiation and mobilization of different myeloid leukocyte subsets including neutrophils, tissue macrophages/dendritic cells or their circulating precursors. gm-csf was found to be crucial for alveolar epithelial repair following hyperoxic and inflammatory lung injury.the aim of the current trial is to prevent progression to ards in covid-19 pneumonia patients by preemptive gm-csf inhalation.

Eligibility criteria:
inclusion criteria: 1. signed informed consent form by the patient according to local regulations 2. man or non-pregnant woman 3. age ≥18 years 4. willingness of patients with reproductive potential to use highly effective contraceptive methods by practicing abstinence or by using at least two methods of birth control from the date of consent to the end of the study. if abstinence could not be practiced, a combination of hormonal contraceptive (oral, injectable, or implants) and a barrier method (condom, diaphragm with a vaginal spermicidal agent) has to be used \*. 5. lab-confirmed covid-19 pneumonia where pneumonia is diagnosed by radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or clinical assessment (evidence of rales/crackles on exam) and pulse oximeter oxygen saturation ≤ 94% at room air in patients that do not have chronic hypoxia; or less than their baseline oxygenation in patients that suffer from chronic hypoxia 6. negative serum pregnancy test in women of childbearing potentia exclusion criteria: 1. pregnancy or breast feeding 2. autoimmune thrombocytopenia, myelodysplastic syndromes with \> 20% marrow blast cells 3. history or presence of hypersensitivity or idiosyncratic reaction to molgramostim (e.g. leucomax®) or to related compounds (e.g. leukine®) 4. patient not able to use nebulizer device as well as immediately foreseeable mechanical ventilation of the patient 5. simultaneous participation in another clinical trial with an experimental treatment

Keywords: gm-csf covid-19 ards
endovascular treatment of peripheral artery disease

Conditions: Peripheral Arterial Disease; Iliac Artery Disease; Below-the-knee Obstruction; Femoropopliteal Occlusive Disease

Summary: the purpose of this observational study is to evaluate the performance and safety of endovascular treatment with stenting (optimed sinus superflex 635) or balloon angioplasty (cardionovum legflow or optimed nylotrack .035 + .018) according to current practice. the goal of the study will be achieved by assessing binary restenosis with duplex ultrasound, peri- and postoperative complications, technical success, target lesion revascularization, amputation and clinical outcome.


Eligibility criteria:
inclusion criteria: 1. patient must sign the informed consent form prior to the index-procedure. 2. patient is older than 18 years. 3. patient is compliant with the requested follow-up visits at week 6 and month 12 and the treatment regime. 4. patient suffers from intermittent claudication (rutherford 2-3) or critical limb ischemia (rutherford 4-5). 5. target lesion is an occlusion or diameter stenosis is ≥70% by visual estimate. 6. target lesion is located in the common and external iliac artery, in the common and superficial femoral artery, popliteal artery and/or the below-the-knee (btk) arteries (anterior tibial artery, posterior tibial artery or peroneal artery) . exclusion criteria: 1. patients with rutherford 0, 1 and 6. 2. patient is pregnant. 3. patients with serum creatinine \>2.0 mg/dl or renal dialysis. 4. patient has an acute thrombus or aneurysm in the target arteries. 5. patient has a life expectancy of \<12 months. 6. patient with bypass that involves the target arteries. 7. patient has a target lesion that cannot be crossed with a guidewire. 8. patient suffers from acute limb ischemia defined as any sudden decrease in limb perfusion causing a potential threat to limb viability. 9. patient has scheduled elective non-vascular procedures within 3 months after index-procedure. vascular procedures are allowed within 3 months after the index-procedure if it is guaranteed that acetylic salicylic acid and clopidogrel intake is not interrupted. 10. contraindication for anti-thrombotic therapy (coagulopathy, ...). 11. patient has a known intolerance to anti-thrombotic medication or contrast agents.
treatment adherence of tuberculosis medicines

Conditions: Tuberculosis

Summary: it was hypothesized that tuberculosis patients receiving multiple interventions like educations, counseling and default tracing along with dots were more likely to adhere to tuberculosis treatment as compared to few interventions or dots only.


Eligibility criteria:
inclusion criteria: * adult patient * \> 18years * either sex * diagnosed to have tuberculosis through chest x ray or sputum microscopy * eligible to participate in the study exclusion criteria:
cadx - radiomics to distinguish the origin of ovarian tumors

Conditions: Ovarian Cancer

Summary: in women with an ovarian tumor, it is often unclear whether the tumor is benign or malignant. to differentiate, tumor markers (ca125 and cea), a transvaginal ultrasound and, depending on the ultrasound image and the ca125 concentration, a ct scan are performed. the quality of radiological imaging in diagnosing abdominal pathology is often not accurate enough, making additional interventions no-dig for proper classification and interpretation of the tumor. objective: to improve accuracy for distinguishing benign from malignant disease in patients presenting with an ovarian mass by using a computer aided detection algorithm.

this research focuses on improving the accuracy of the determination of the nature (benign or malignant) of ovarian tumors by making use of artificial intelligence by creating a ct-scan algorithm. this because a correct preoperative classification of ovarian tumors is essential for appropriate treatment. existing prediction models often lead to unnecessary referrals to gynecological oncology hospitals, resulting in higher costs and increased stress for the patient. it is therefore important to evaluate other strategies to differentiate between benign and malignant ovarian tumors. artificial intelligence (ai) for radiology is currently being developed by the eindhoven university of technology (tu/e) and philips research europe and may provide a potential solution to this problem. the currently developed algorithm (cadx), using a support vector machine (svm), showed within a small population of about 100 patients a sensitivity of 74% and specificity of 74%. these are promising results to train this algorithm even further with more ct-scans images and the addition of clinical variables and even liquid biopsies. type of study: retrospective study cohort this is a retrospective analysis on known data in which definitive patients diagnosis has already been established and current analysis will not affect treatment plan. no products for patients are used, only computer aided diagnosis is used on existing radiological imaging, namely ct-scans. this study is linked to two other dutch trials in which ovarian tumor biomarkers are assessed in order to find out the origin of ovarian tumors preoperatively. the first is the he4-prediction study, with local protocol id nl58253.031.16. the second is the ovi-detect study, with clinicaltrial.gov number nct04971421.

Eligibility criteria:
inclusion criteria: * patients with an ovarian tumor of which it is unknown whether it is benign or malignant (risk of malignancy index (rmi) \>200) * underwent surgery * histological proof of tumor exclusion criteria: * indefinite pathology report * lack of correct description of staging in or report when applicable
vaccine therapy in treating patients with chronic phase chronic myelogenous leukemia

Conditions: Leukemia

Summary: rationale: vaccines made from a peptide may help the body build an effective immune response to kill cancer cells. purpose: this phase ii trial is studying how well vaccine therapy works in treating patients with chronic phase chronic myelogenous leukemia.

objectives: * determine the antileukemic effects of tumor-specific breakpoint cluster region-abelson murine leukemia(bcr-abl) junction specific peptide vaccine, as measured by a decrease in circulating bcr-abl transcripts by reverse-transcriptase polymerase chain reaction (rt-pcr), that persist for at least 3 months, in patients with chronic phase chronic myelogenous leukemia. * determine the percentage of patients treated with this vaccine who become rt-pcr-negative for bcr-abl transcripts. * compare response in patients with b3a2 junctions vs b2a2 junctions when treated with this vaccine. * determine the immunologic response over 1 year in patients treated with this vaccine. * correlate response with specific hla types in these patients. * determine the safety of this vaccine in these patients. outline: this is a pilot, multicenter study. patients receive bcr-abl junction-specific peptide vaccine subcutaneously in weeks 2, 4, 6, 8, and 11 and then once monthly for 10 months. bcr-abl transcript levels are assessed by quantitative reverse-transcriptase polymerase chain reaction at baseline, weeks 2, 4, and 6, every 3 months during treatment, and then 2 weeks after completion of study treatment. projected accrual: a total of 20 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of philadelphia chromosome-positive or bcr-abl-positive chronic phase chronic myelogenous leukemia (cml) * in complete cytogenetic remission confirmed by 2 bone marrows ≥ 1 month apart * minimal residual disease * detectable bcr-abl transcript levels obtained \< 6 months apart and ≤ 0.5-log lower than the lowest value obtained within the past 6 months patient characteristics: * karnofsky performance status 80-100% * bilirubin \< 2 times upper limit of normal (uln) * creatinine \< 1.5 times uln * alt and ast \< 2.5 times uln prior concurrent therapy: * recovered from prior therapy * no major surgery within the past 4 weeks * no prior chemotherapy * no prior immunosuppressive therapy * no prior corticosteroids * no prior stem cell transplantation * no radiotherapy within the past 4 weeks * no other concurrent investigational agents

Keywords: philadelphia chromosome positive (ph+) chronic myelogenous leukemia chronic phase chronic myelogenous leukemia
aurora test for art donor patients (aurora-donor)

Conditions: Infertility

Summary: this is a randomized observational study. the main aim is to determine potential oocyte competence predictive mrna expression profiles in the cumulus cells isolated form individual oocytes. in 2 patient cohorts: 1)gnrh antagonist \& hr-fsh with gnrh agonist trigger, 2) progesterone \& hr-fsh with gnrh agonist trigger.


Eligibility criteria:
inclusion criteria donor: * patients are 18 to 35 years old * bmi between 17-30 * regular menstrual cycles * afc \> 8 * patient profile in compliance with sef (sociedad española de fertilidad) directives for egg donation (medical, psychological and genetic screening, informed consent) * patients' stimulation: gnrh antagonist \& hr-fsh with gnrh agonist trigger or progesterone \& hr-fsh with gnrh agonist trigger * patients agree that the oocytes will be denuded for cumulus testing and provide written informed consent for participation to the study exclusion criteria donor: * bmi \ 30 * extreme irregular menstrual cycles (\ 40 days) * afc \< 8 * \<8 mii on previous egg retrieval * women with history of poor oocyte maturation or known maturation defect or unexplained failure in previous treatments * patients that fail to comply with sef (sociedad española de fertilidad) directives for egg donation (medical, psychological and genetic screening, informed consent) inclusion criteria recipient: * patients applying for art egg donation with fresh/frozen sperm from the partner or frozen donor sperm. with esb-fet in modified natural cycle or an hrt cycle. * patients are from 18 to 50 years old. * patients will be treated by icsi (intracytoplasmic sperm injection) and esb-fet (elective single blastocyst frozen embryo transfer) * recipient patients agree that the donors' oocytes will be denuded for cumulus testing and provide written informed consent for participation to the study exclusion criteria for oocyte recipients * patient included in any other prospective study. * bmi \ 35 * severe uterine factor: multiple myomectomy, multiple fibroids, major uterine malformation (unicorn, septum), asherman sd, severe adenomyosis * repeated implantation failure or repeated pregnancy loss after euploid single blastocyst transfer * severe male factor: abnormal caryotype or fish, severe oat / cripto-azoospermia, dna fragmentation \>50% after medical treatment * tese / tesa (testicular sperm extraction/aspiration)
a phase ii study of docetaxel plus carboplatin in chemonaive hormone-refractory prostate cancer (hrpc) patients

Conditions: Hormone-Refractory Prostate Cancer

Summary: the primary objective is to determine the efficacy of docetaxel plus carboplatin as first line treatment in patients with hormone refractory prostate cancer.

docetaxel-prednisolone is the current standard in hrpc, based on 2 large randomized trials showing improved survival compared to mitoxantrone-prednisolone. carboplatin has activity in prostate cancer and the combination of docetaxel-carboplatin is known to be synergistic and is used with good effect in many cancers. the advantage of using this combination in prostate cancer is suported by clinical data: high response rates of docetaxel-carboplatin-estramustine (with g-csf support) in a phase ii trial (oh, halabi, kelly et al. cancer. 2003 dec 15;98(12):2592-8), and additional effect of this combination in prior taxane failures (oh, george, tay. clin prostate cancer. 2005 jun;4(1):61-4). carboplatin itself has activity and theoretically could target the more hormone resistant clones or neuroendocrine components of the tumor.(di sant' agnese. j urol. 1994 nov;152(5 pt 2):1927-31.) we are studying the combination of docetaxel-carboplatin both given in a weekly, low-dose fashion, without estramustine and without g-csf. this is expected to be an effective and tolerable treatment for hrpc patients. we will be documenting (to our knowledge) for the first time in this trial the efficacy of the combination given in this particular dose and schedule.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed adenocarcinoma of the prostate. 2. at the time of enrollment, patients must have evidence of metastatic disease, with either measurable disease per recist criteria or non- measurable disease (i.e. positive bones scan) and psa \> 5 ng/mm3. 3. disease progression following androgen deprivation therapy. 4. progression is defined according to the psa working group criteria (see 6.1.3 and 6.3). 5. serum testosterone levels \< 50 ng/mm3 (unless surgically castrate). patients must continue androgen deprivation with an lhrh analogue if they have not undergone orchiectomy. 6. no use of an antiandrogen for at least 4 weeks. 7. have not been treated with chemotherapy before. 8. ecog performance status of \<= 2. 9. laboratory criteria for entry: * white blood cell (wbc) =\> 3000/mm3 * platelets =\> 100,000/mm3 * ast \< 2.5 x upper limit of normal * calculated cct of =\> 40 ml/min 10. signed informed consent form. 11. age: 30 years old and above exclusion criteria: 1. significant peripheral neuropathy defined as grade 2 or higher. 2. within 4 weeks since completing external beam radiotherapy or 8 weeks since completing radiopharmaceutical therapy (strontium, samarium). 3. concomitant chemotherapy or investigational agents.